FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048009608> ?p ?o ?g. }

• W3048009608 endingPage "e19.00068" @default.
• W3048009608 startingPage "e19.00068" @default.
• W3048009608 abstract "Giant-cell tumor of bone (GCTB) is a locally aggressive intermediate bone tumor with a rarely metastasizing disposition. Standard surgical treatment consists of curettage, adjuvant treatment, and augmentation with allograft, autograft, or synthetics. Polymethylmethacrylate (PMMA) has been widely used for augmentation of the bone defect; however, the hyperthermic polymerization of PMMA may cause damage to articular cartilage, and the stiffness of the material may decrease the ability of the joint to absorb shock. These properties were reported to result in secondary osteoarthritis. Calcium phosphate cement has a low degree of thermal reaction and a strength that is similar to cortical bone. The aim of the present study was to investigate the incidence of secondary osteoarthritis around the knee joint following augmentation with calcium phosphate cement.We retrospectively evaluated 19 patients with primary GCTB from 2003 to 2012. Curettage, high-speed burring, phenolization, and filling with calcium phosphate cement were performed in all patients. Radiographic evidence of osteoarthritis progression was evaluated with use of the Kellgren-Lawrence grade; the postoperative grade was compared with both the preoperative grade and the grade of the nonoperative contralateral knee at the time of the latest follow-up. The Musculoskeletal Tumor Society score and oncological outcomes at the time of the latest follow-up were evaluated.At a median follow-up period of 131 months, osteoarthritic progression was observed in 5 patients (26%), of which 2 were classified as Kellgren-Lawrence grade 3 and 1 was classified as Kellgren-Lawrence grade 4. The patient with grade-4 osteoarthritis underwent total knee arthroplasty, and 1 of the patients with grade-3 osteoarthritis underwent open-wedge high tibial osteotomy. The 10-year survival rate of joint cartilage with a Kellgren-Lawrence grade of <3 was 83%. The average Musculoskeletal Tumor Society score was 29 points. GCTB recurred in 2 patients, and 1 of these patients developed pulmonary metastasis.The incidence of secondary osteoarthritis was low, despite the long follow-up period. Prospective investigation comparing PMMA and calcium phosphate cement is warranted to determine the relative rate of secondary osteoarthritis and the outcomes associated with the 2 different types of augmentation.Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence." @default.
• W3048009608 created "2020-08-13" @default.
• W3048009608 creator A5010692199 @default.
• W3048009608 creator A5013475332 @default.
• W3048009608 creator A5028483263 @default.
• W3048009608 creator A5032191719 @default.
• W3048009608 creator A5054652384 @default.
• W3048009608 creator A5056400625 @default.
• W3048009608 creator A5060073306 @default.
• W3048009608 creator A5081080411 @default.
• W3048009608 creator A5088078553 @default.
• W3048009608 creator A5089158442 @default.
• W3048009608 date "2020-01-01" @default.
• W3048009608 modified "2023-10-02" @default.
• W3048009608 title "Secondary Osteoarthritis After Curettage and Calcium Phosphate Cementing for Giant-Cell Tumor of Bone Around the Knee Joint" @default.
• W3048009608 cites W1965247641 @default.
• W3048009608 cites W1967057044 @default.
• W3048009608 cites W2008510980 @default.
• W3048009608 cites W2044894450 @default.
• W3048009608 cites W2045383686 @default.
• W3048009608 cites W2049936830 @default.
• W3048009608 cites W2053814415 @default.
• W3048009608 cites W2055405303 @default.
• W3048009608 cites W2056738164 @default.
• W3048009608 cites W2080074604 @default.
• W3048009608 cites W2081101372 @default.
• W3048009608 cites W2090719467 @default.
• W3048009608 cites W2115022146 @default.
• W3048009608 cites W2117125451 @default.
• W3048009608 cites W2121960517 @default.
• W3048009608 cites W2123114700 @default.
• W3048009608 cites W2129142927 @default.
• W3048009608 cites W2140463255 @default.
• W3048009608 cites W2145043990 @default.
• W3048009608 cites W2166687994 @default.
• W3048009608 cites W2182973607 @default.
• W3048009608 cites W2240505534 @default.
• W3048009608 cites W2287011969 @default.
• W3048009608 cites W2414485509 @default.
• W3048009608 cites W2432719443 @default.
• W3048009608 cites W2547051631 @default.
• W3048009608 cites W2591717879 @default.
• W3048009608 cites W2601131603 @default.
• W3048009608 cites W2743917006 @default.
• W3048009608 cites W2748240881 @default.
• W3048009608 cites W2765950759 @default.
• W3048009608 cites W2770659829 @default.
• W3048009608 cites W2783769557 @default.
• W3048009608 cites W2793466037 @default.
• W3048009608 cites W2800574047 @default.
• W3048009608 cites W2800931371 @default.
• W3048009608 cites W2809742628 @default.
• W3048009608 cites W2900417746 @default.
• W3048009608 cites W2912043101 @default.
• W3048009608 cites W2914114989 @default.
• W3048009608 cites W2944528337 @default.
• W3048009608 cites W2980715221 @default.
• W3048009608 cites W2989258869 @default.
• W3048009608 cites W4292542148 @default.
• W3048009608 cites W4294956794 @default.
• W3048009608 doi "https://doi.org/10.2106/jbjs.oa.19.00068" @default.
• W3048009608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7480969" @default.
• W3048009608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32984748" @default.
• W3048009608 hasPublicationYear "2020" @default.
• W3048009608 type Work @default.
• W3048009608 sameAs 3048009608 @default.
• W3048009608 citedByCount "9" @default.
• W3048009608 countsByYear W30480096082022 @default.
• W3048009608 countsByYear W30480096082023 @default.
• W3048009608 crossrefType "journal-article" @default.
• W3048009608 hasAuthorship W3048009608A5010692199 @default.
• W3048009608 hasAuthorship W3048009608A5013475332 @default.
• W3048009608 hasAuthorship W3048009608A5028483263 @default.
• W3048009608 hasAuthorship W3048009608A5032191719 @default.
• W3048009608 hasAuthorship W3048009608A5054652384 @default.
• W3048009608 hasAuthorship W3048009608A5056400625 @default.
• W3048009608 hasAuthorship W3048009608A5060073306 @default.
• W3048009608 hasAuthorship W3048009608A5081080411 @default.
• W3048009608 hasAuthorship W3048009608A5088078553 @default.
• W3048009608 hasAuthorship W3048009608A5089158442 @default.
• W3048009608 hasBestOaLocation W30480096081 @default.
• W3048009608 hasConcept C120665830 @default.
• W3048009608 hasConcept C121332964 @default.
• W3048009608 hasConcept C141071460 @default.
• W3048009608 hasConcept C142724271 @default.
• W3048009608 hasConcept C166957645 @default.
• W3048009608 hasConcept C204787440 @default.
• W3048009608 hasConcept C2776164576 @default.
• W3048009608 hasConcept C2778891590 @default.
• W3048009608 hasConcept C2779904257 @default.
• W3048009608 hasConcept C523993062 @default.
• W3048009608 hasConcept C61511704 @default.
• W3048009608 hasConcept C71924100 @default.
• W3048009608 hasConcept C95457728 @default.
• W3048009608 hasConceptScore W3048009608C120665830 @default.
• W3048009608 hasConceptScore W3048009608C121332964 @default.
• W3048009608 hasConceptScore W3048009608C141071460 @default.
• W3048009608 hasConceptScore W3048009608C142724271 @default.

• next